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Abstract
High-grade serous cancer (HGSC) accounts for ~67% of all ovarian cancer deaths. Although initially sensitive to
platinum chemotherapy, resistance is inevitable and there is an unmet clinical need for novel therapies that can
circumvent this event. We performed a drug screen with 1177 FDA-approved drugs and identified the
hydroxyquinoline drug, chloroxine. In extensive validation experiments, chloroxine restored sensitivity to both cisplatin
and carboplatin, demonstrating broad synergy in our range of experimental models of platinum-resistant HGSC.
Synergy was independent of chloroxine’s predicted ionophore activity and did not relate to platinum uptake as
measured by atomic absorption spectroscopy. Further mechanistic investigation revealed that chloroxine overrides
DNA damage tolerance in platinum-resistant HGSC. Co-treatment with carboplatin and chloroxine (but not either drug
alone) caused an increase in γH2AX expression, followed by a reduction in platinum-induced RAD51 foci. Moreover,
this unrepaired DNA damage was associated with p53 stabilisation, cell cycle re-entry and triggering of caspase 3/7-
mediated cell death. Finally, in our platinum-resistant, intraperitoneal in vivo model, treatment with carboplatin alone
resulted in a transient tumour response followed by tumour regrowth. In contrast, treatment with chloroxine and
carboplatin combined, was able to maintain tumour volume at baseline for over 4 months. In conclusion, our novel
results show that chloroxine facilitates platinum-induced DNA damage to restore platinum sensitivity in HGSC. Since
chloroxine is already licensed, this exciting combination therapy could now be rapidly translated for patient benefit.
Introduction
Ovarian cancer is the seventh most common cancer
type amongst women1 and the most common histological
subtype is high-grade serous cancer (HGSC)2. Standard
treatment is still reliant on combination surgery and
platinum-based chemotherapy3. Despite this aggressive
approach, 85% of patients will subsequently relapse and
sequential platinum treatment inevitably results in
chemotherapy resistance4. Circumventing this pervasive
problem is an unmet clinical challenge.
Platinum compounds covalently bind DNA, generating
protein–DNA or DNA–DNA complexes, along with
inter- and intra-strand adducts5,6. This ultimately gen-
erates DNA lesions, followed by activation of the DNA
damage response (DDR)5,6. Apoptosis eventually occurs
when damage exceeds repair. Platinum resistance is a
multifactorial process that has been extensively investi-
gated7. Many potential mechanisms underlie this event,
including failure to uptake or accumulate platinum8,
augmented DNA damage repair machinery9, increased
tolerance to unrepaired DNA lesions10, defects in signal
transduction7, inactivation of pro-apoptotic events11 and
upregulation of autophagic pathways6. The elucidation of
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these mechanisms is yet to support the discovery of more
efficient treatments for resistant HGSC3.
Repurposing non-oncological drugs for clinical appli-
cations is an exciting and cost-effective strategy that can
provide rapid clinical translation12. We have previously
developed a unique panel of platinum-resistant cell lines
and in vivo models and shown that they closely resemble
the genetic, transcriptional and clinical features of human
HGSC13. Using these novel cell lines, we employed a drug
screening approach to identify hit drugs that could
potentially reverse platinum resistance. The compound
library encompassed 1177 small molecules, 90% of which
are marketed drugs, many with unknown anticancer
properties. We identified chloroxine, a 8-hydroxy-
quinoline (8-HQ) with antibacterial and antifungal activ-
ities14. To our knowledge, there are no reports regarding
the activity of chloroxine as an anticancer agent and very
little is known about its inherent cellular mechanism.
Herein, we reveal for the first time, the synergy between
chloroxine and platinum agents in resistant HGSC both
in vitro and in vivo. We unravel the novel mechanism of
action of chloroxine in overriding the inherent tolerance
to DNA damage in platinum-resistant cancer cells and
facilitating cancer cell death by apoptosis. Moreover,
chloroxine showed tumour-static effect in vivo, when
used in combination with carboplatin; thus, chloroxine
could have significant impact on the treatment of patients
with platinum-resistant HGSC.
Materials and methods
Cell culture and platinum-resistant cell lines
Human HGSC cell lines OVCAR4 and COV318 were
obtained from Prof. Fran Balkwill (Barts Cancer Institute,
UK). Platinum-resistant HGSC cell lines (Ov4Cis,
Ov4Carbo and CovCis) were generated by serial culture in
increasing concentrations of either cisplatin or carbopla-
tin, as we described previously13 and subsequently cul-
tured in drug-free media. Cells were grown at 37 °C in a
humidified incubator with 95% air and 5% CO2 in DMEM
(Gibco) supplemented with 10% FBS (Gibco) and 1%
penicillin/streptomycin (Gibco). All cell lines underwent
16-locus STR verification (DNA Diagnostics Centre,
London, UK: February 2016 and European Collection of
Authenticated Cell Lines August 2019) and weekly
mycoplasma testing.
Compound library screen
To screen HGSC cell lines for existing drugs that
synergise with carboplatin, we used a 96-well plate cell
viability assay based on our previous work15. The che-
mical library encompassed 1177 small molecules, 90% of
which were marketed drugs, the remaining 10% being
bioactive alkaloids. Platinum-sensitive (OVCAR4) and
platinum-resistant (Ov4Carbo) cells were seeded in
96-well plates (103 cells/well). On day 2, cells were
exposed to either a library compound or equimolar
dimethyl sulfoxide (DMSO) vehicle control. On day 5,
cells were re-treated with the same library compound
together with either carboplatin (5 µM) or vehicle. In all,
5 µM carboplatin was chosen because this dose resulted in
minimal cell death in both cell lines (Supplementary Fig.
S1A). Each drug in the compound library was therefore
tested alone and in combination with carboplatin in both
cell lines, in one well of the 96-well plate per experimental
condition. The final compound concentration used was
10 µM, based on our previous work15 as a dose in which
the effects on cell viability are highly likely to be observed.
We expected that many of the initial hit drugs, identified
at this drug dose in only one well per experimental con-
dition, would be excluded in subsequent validation
experiments (see below).
After 7 days’ continuous culture, cell viability in each
well was estimated using a luciferase-based ATP assay
(CellTitre-Glo, Promega) according to the manufacturer’s
instructions. For each well in the 96-well plate, the effect
of treatment was represented as a log2-surviving fraction
(s.f.) and expressed relative to the median s.f. for the entire
96-well plate. In each cell line, s.f. was compared between
library-treated and vehicle-treated wells and also between
wells treated with either library+carboplatin or carbo-
platin alone (Supplementary Table 1). To identify the
selective ability to synergise with carboplatin, we pre-
defined a cut-off of s.f. <−2 following library + carbo-
platin together with s.f. >−2 for library compound alone.
Using these criteria, 11 drugs were considered ‘hits’ and
selected for further investigation in validation experi-
ments (Supplementary Table 2).
Synergy validation experiments
Validation experiments were carried out by plating
OVCAR4 and Ov4Carbo cells in 96-well plates (103 cells/
well) in triplicate wells per condition. Cells were treated
using the same experimental protocol as the initial com-
pound library screen (day 2: hit drug (1–10 μM) or vehi-
cle, day 5: carboplatin (0.01–1000 μM) + either hit drug
(same dose as on day 2) or vehicle). Cell viability was again
estimated using CellTitre-Glo on day 7. Dose–response
curves were generated and IC50 calculated using Graph-
Pad Prism v.8.0 (nonlinear regression fit to a five-
parameter equation). At least three biological repeat
experiments were conducted per potential hit compound
and analysed using Calcusyn® software to generate iso-
bolograms where a CI (combination index) >1 indicates
synergy, CI= 1 indicates addition and CI < 1 indicates
antagonism. All 11 potential hit drugs (Supplementary
Table 2) were tested in validation experiments. Chlorox-
ine was selected for further investigation because it was
the only drug that demonstrated synergy with platinum
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chemotherapy specifically in HGSCs with pre-existing
resistance.
Preparation of chloroxine in Intralipid®
Chloroxine (5,7-dichloro-8-quinolinol, Sigma-Aldrich)
was weighed in amounts of 0 (blank), 10, 30, 50 and
100mg/kg in separate glass vials. Larger clumps were
broken down using a spatula. In total, 15 ml of Intralipid
emulsion (Sigma-Aldrich) was added to each glass vial,
vortex-mixed for 5 min and bath-sonicated for at least 2 h
at 40 °C. A previous report16 showed that there was no
effect of bath sonication on the stability of these emul-
sions. Optimum solubility was obtained at 10 mg/kg.
Murine experiments
OVCAR4 and Ov4Carbo cells were previously modified
using lentiviruses to express dual GFP/Luciferase and RFP/
Luciferase reporters, respectively13. All experiments were
conducted under UK government Home Office license
(P1EE3ECB4) following Institutional Review Board approval.
Cells were inoculated by intraperitoneal (IP) injection into 6-
week-old female CD1nu/nu mice (Charles River Laboratories)
in sterile PBS (5 × 106 cells/200 µl). Tumour growth was
monitored weekly via bioluminescence using IP injections of
D-Luciferin monopotassium salt (3.7mg/200ml, Thermo-
Fisher) in PBS. Light emission was recorded using an IVIS®
Spectrum (PerkinElmer). Mice were randomly allocated (by
order of cage number and existing earmarking) to treatment
groups. In an initial optimisation experiment, mice received
either carboplatin (50mg/kg in 0.2ml PBS IP weekly, n= 10)
or PBS control (0.2ml daily IP, n= 5). We then selected a
sample size of five mice per group for our first in vivo eva-
luation of chloroxine-delivered IP in Intralipid. Mice in this
second experiment received carboplatin (50mg/kg in 0.2ml
PBS IP weekly, n= 5), chloroxine (10mg/kg in 0.2ml
Intralipid IP once daily, n= 5), combination (daily chloroxine
and weekly carboplatin, 0.4ml IP, n= 5) or PBS control
(0.2ml daily IP, n= 5). In both experiments, treatment
commenced once tumours were established, as determined
by our predefined light output cut-offs (average radiance
between 105 and 107 p/s/cm2/sr). Three mice were excluded
for not meeting these parameters (one from the carboplatin
group, one from the combination group and once from the
PBS control group). The appearance of chloroxine in Intra-
lipid solution (see Fig. 2B) prevented blinding of experi-
mental groups. Treatment continued for 4 weeks. Mice were
assessed for weight, general health and accumulation of
ascites, and were killed once they reached humane endpoint
(defined by the UK Home Office guidelines).
Platinum uptake
In total, 1 × 106 OVCAR4 and Ov4Carbo cells were
plated in 10-cm dishes (Corning) and treated after 24 h
with 10 μM chloroxine, 100 μM carboplatin or both drugs
combined. Up to 48 h later, cells were washed twice with
ice-cold PBS. Cells were scraped into 200 μl lysis buffer
(150 mM NaCl, 50 mM Tris, 0.05% SDS and 1% triton). In
total, 20 μl lysate was collected for protein quantification
(Pierce bicinchoninic acid (BCA) kit (Thermo Scientific)).
The remainder was spun (13,000×g at 4 °C for 5 min) and
the supernatant (whole-cell fraction) collected. Samples
were adjusted to 1 ml with 0.5% nitric acid (HNO3) to
ensure platinum (Pt) solubilisation. Pt content was ana-
lysed using atomic absorption spectroscopy, AAS (Varian
Spectra AAS 220 FS) with a hollow cathode platinum
lamp operated at 10 mA. Platinum absorbance was
monitored at 265.9 nm corrected for any background
signals, with a slit width of 0.2 nm. Argon was used as the
inert gas with a constant flow of 3 ml/min. Elemental
platinum standards (20–1000 µg/L) were prepared by
serial aqueous dilution using High-Purity Standards pla-
tinum standard (1000 µg/ml, Sigma-Aldrich) and carbo-
platin stock (10 mg/ml). In all, 20 μl samples were injected
for three measurements per sample on two dishes per
condition in duplicate experiments. Pt concentrations
were determined by applying an elemental platinum
standard curve and normalised to protein levels.
Copper complexation
Cu-8-HQ (chloroxine) complexes were prepared as
described previously17. Two equivalents of chloroxine
(20 mg, 0.0935mmol) were added slowly to a stirred
solution of CuCl2 (8 mg, 0.0468mmol) in 10 ml of an
ethanolic solution and stirred for over 3 h. To assess
cytotoxicity, OVCAR4 and Ov4Carbo cells (1000/well)
were plated in 96-well plates in triplicate and treated with
cupric chloroxine (10 μM) ± carboplatin as before (see
synergy validation, n= 3 biological repeats). Cell viability
was determined using CellTiter-Glo and dose–response
curves generated.
Copper enrichment assays
To simulate the in vivo copper status of cancer cells,
OVCAR4 and Ov4Carbo cells were cultured in media
containing 25 μM CuCl2 for 1 week, as previously
described18. Cells (1000/well) were then plated in 96-well
plates and treated with chloroxine (10 μM) ± carboplatin
in triplicate as before (see synergy validation, n= 3 bio-
logical repeats). For short-term enrichment, cells were
plated in 96-well plates and pre-treated with 10 μM CuCl2
for 48 h. Cell viability was determined on day 7 using
CellTiter-Glo and dose–response curves generated.
OPRK1
OVCAR4 and Ov4Carbo cells (1000/well in triplicate)
were seeded in 96-well plates (triplicate) and treated with
chloroxine (10 μM) ± carboplatin as before (see synergy
validation, n= 8 biological repeats). The selective κ-opioid
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agonist: U50,488 ((±)-trans-U-50488 methanesulfonate salt,
Sigma-Aldrich) and antagonist: nor-binaltorphimine
(nor-BNI, Sigma-Aldrich) were used at 10 μM in place of
chloroxine and in combination with carboplatin on day 5.
Control plates displaying dose–response curves for each
individual compound were seeded in parallel. Cell viability
was determined on day 7 using CellTiter-Glo assay and
dose–response curves generated.
Western blot
OVCAR4 and Ov4Carbo (4 × 105 cells/well) were see-
ded in six-well plates. Cells were washed with PBS and
sonicated (Bioruptor Pico-RM 343 for 10min) in ice-cold
lysis buffer (150 mM NaCl, 50 mM Tris, 0.05% SDS and
1% triton), supplemented with 1% protease/phosphatase
inhibitor cocktail (Roche). Samples were centrifuged
(13,000×g, 4 °C, 20 mins) and protein concentration
determined (Pierce BCA assay kit (Thermo Scientific)). In
total, 30 μg/20 μl protein were prepared in SDS loading
buffer, boiled for 5 min, separated on 4–12% Bis–Tris gels
(Life Technologies) and transferred to nitrocellulose
membranes (GE Healthcare) by semi-dry transfer (Trans-
Blot® SD Cell, BioRad). Membranes were blocked in 5%
non-fat milk/PBS for 1 h at room temperature and incu-
bated with primary antibodies for p53 (1:1000, Sc-126
Santa Cruz, n= 4 biological repeats), RAD51 (1:1000,
PA5-27195, Invitrogen, n= 3 biological repeats), GADPH
(1:2000, Sc-47724 Santa Cruz), Tubulin (1:2000, ab52866
Abcam) and γH2AX (ser139 1:500, JBW301 Millipore, n
= 8 biological repeats) at 4 °C overnight, followed by
incubation with secondary anti-mouse HRP (1:2000,
P0260 DAKO) and anti-rabbit HRP (1:1000, P0448
DAKO) for 1 h at room temperature. Proteins were
visualised by enhanced chemiluminescence (GE Health-
care), imaged (Amersham Image 600, GE Healthcare) and
quantified by densitometry (ImageQuant TL software
package).
Immunofluorescence for DNA damage
OVCAR4 and Ov4Carbo cells (8 × 104 cells/well) were
seeded in duplicate on poly-l-lysine-coated coverslips and
allowed to adhere overnight. Cells were then treated with
chloroxine (10 μM), carboplatin (50 μM or 100 μM) or
combination [(chloroxine (10 μM)+ carboplatin 50 μM
or 100 μM)] for 4 and 24 h. The medium was aspirated
and 0.1% Triton (Sigma-Aldrich) in PBS added for 1 min
prior to fixing in 3% paraformaldehyde/2% sucrose for
30min. Cells were then blocked with 3% BSA/PBS for 1 h.
Next, staining was performed with antibodies for γH2AX
(1:800, Millipore JBW301) and RAD51 (1:1000, Invitrogen
PA5-27195) for 40min at 37 °C. Cells were incubated with
secondary antibodies (AlexaFluor-488 and AlexaFluor-
568, Invitrogen) for 30min at 37 °C, and co-stained with
DAPI (1:10,000, 1 mg/ml Sigma). Coverslips were
mounted with Mowiol and images captured using a Zeiss
710 confocal microscope. Foci were counted and scored
manually using ImageJ software. At least 100 nuclei were
counted for each condition (using duplicate plate wells)
and cells with >5 foci/nucleus were considered positive
(three biological replicates were conducted).
Flow cytometry (cell cycle)
Cells were treated with chloroxine (10 μM), carboplatin
(100 μM) or the combination (chloroxine 10 μM+ car-
boplatin 100 μM) and triplicate samples were harvested
24 h and 48 h post treatment in two biological repeat
experiments. Cells were centrifuged (1000 × g for 5 min),
washed three times with cold PBS and fixed in 70% (v/v)
ethanol/PBS. Next, cells were re-suspended in 0.25 ml
PBS containing 25 μg RNase and 12.5 μg propidium
iodide. Following 30 min of incubation at 37 °C, cell cycle
profiles were acquired with LSR FortessaTM (BD Bios-
ciences), using a 670-nm long-pass filter and counting
10,000 cells per sample. Data were analysed using
FlowJo v8.
Caspase 3/7 assay
The synergy validation protocol detailed above was used
to determine caspase 3/7 activity. Briefly, 1000 cells were
plated, in triplicate, in 96-well plates and treated with
chloroxine (1–50 μM), carboplatin (10–300 μM) or with
the combination. Caspase 3/7 activity was determined
using Caspase-Glo® 3/7 Assay System (Promega) up to
7 days later. Duplicate plates were seeded to determine
cell viability using CellTiter-Glo and three biological
repeats were carried out.
Statistics
All data were presented as mean ± s.d. and analyses
were performed using GraphPad Prism 8.0. Groups were
compared to establish comparable variance and statistical
significance was calculated using a two-tailed unpaired
t test, one-way ANOVA (followed by post hoc
Kruskal–Wallis test) or two-way ANOVA (followed by
Tukey post hoc test) for group analysis and defined as
follows: P < 0.0001 (****), P < 0.001 (***), P < 0.01 (**), P <
0.05 (*) or P > 0.05 (ns). n refers to biological replicates
and the established scientific standard of n ≥ 3 was applied
throughout.
Results
Chloroxine synergises with carboplatin in platinum-
resistant HGSC in vitro
We employed a library of 1177 compounds to identify
drugs that can restore sensitivity to carboplatin in
HGSC15. Cell viability was assessed using CellTiter-Glo®
and the effect of each compound was determined by
comparing luminescence output following drug,
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carboplatin, drug+ carboplatin and vehicle treatment in
OVCAR4 and Ov4Carbo cells. This effect was represented
as a log2-surviving fraction (s.f.) and expressed relative to
the median s.f. for the entire 96-well plate (Fig. 1A and
Supplementary Table 1). In total, 11 potential “hit”
compounds were identified that fulfilled our predefined
criteria of s.f. <−2 following library+ carboplatin together
with s.f. >−2 for library compound alone (Supplementary
Table 2). All 11 compounds were tested in validation
experiments and only chloroxine (Fig. 1B) was validated
as a “hit”.
Chloroxine potentiated the effect of carboplatin in
Ov4Carbo (carboplatin-resistant) cells in multiple repeat
experiments (Fig. 1C, D). To determine if this combina-
tion was additive or synergistic, we analysed individual
and combinatorial drug effects using CompuSyn soft-
ware19. Chou–Talalay isobolograms (Fig. 1E) showed that
the combination of chloroxine and carboplatin was
synergistic at chloroxine doses of 10 μM and above
(Supplementary Fig. S1), and that synergy was superior in
carboplatin-resistant compared to -sensitive cells (Fig.
1F). These data strongly support chloroxine as a candidate
Fig. 1 Drug screen and in vitro synergy between chloroxine (Chl. 10 µM) and carboplatin on the viability of OVCAR4 (sensitive) and
Ov4Carbo (resistant) ovarian cancer cells. A z-score (surviving fraction, s.f.) plot evidencing drug screen output. Each black dot represents one
small-molecule drug in the library. Potential hits are highlighted in the area of interest (green star indicates target drug: chloroxine). B Chemical
structure of 5,7-dichloro-8-quinolinol (chloroxine). C Carboplatin dose response. D IC50 plot. E Fa–CI plot or Chou–Talalay displaying combination
index (in log) vs. fraction of affected cells (Fa); F heatmap demonstrating synergy in multiple biological repeats (n= 13). Cell viability was determined
using CellTiter-Glo®. IC50 was calculated using GraphPad Prism v.8.3.0. mean ± s.d, unpaired t test, ****P < 0.0001. The combination index (CI) was
determined using Calcusyn software, where values <1 (log 0) reflect drug synergy.
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drug to restore carboplatin sensitivity in HGSC. Impor-
tantly, the striking synergistic effect of chloroxine was also
observed with cisplatin in additional platinum-resistant
HGSC cell lines, including Ov4Cis (Supplementary Fig.
S2A, B) and CovCis (Supplementary Fig. S2C, D).
Chloroxine stabilises tumour burden in carboplatin-
resistant intraperitoneal xenografts
To assess chloroxine’s activity in vivo, clinically relevant
HGSC orthotopic intraperitoneal models were created, as
we previously described13. The predetermined in vivo
treatment and tumour surveillance schedule are depicted
in Fig. 2A. Chloroxine solubility was limited in saline and
so was prepared instead in a 20% intralipid solution (as
previously described for other hydroxyquinolines)20 at
concentrations equivalent to 10, 30, 50 and 100mg/kg.
Well-solubilised solutions were observed up to 30 mg/kg
(Fig. 2B).
HGSC IP xenografts were then created in female nude
mice (day 0) using Ov4Carbo-resistant cells expressing
firefly luciferase (Luc). Tumour growth was monitored
with weekly bioluminescence imaging (BLI), and mice
were killed when they reached humane endpoints pre-
defined by the UK Home Office. Mice bearing established
tumours on day 19 (average radiance 105–107p/s/cm2/sr)
(Fig. 2C) were randomly allocated into four treatment
groups on day 21. Animal numbers were insufficient to
compare survival between the treatment groups. How-
ever, we observed that chloroxine-treated mice depicted a
steady increase in tumour growth over time, comparable
to that of the vehicle-treated group (Fig. 2C, D).
Ov4Carbo-Luc xenografts initially responded to carbo-
platin, but subsequently developed resistance to treatment
and light emission increased from day 70 onwards, such
that it overlapped with vehicle-treated control mice. In
contrast, when chloroxine was used in combination with
carboplatin, light output was maintained at baseline
(average radiance below 103p/s/cm2/sr) for the duration
of the experiment (Fig. 2C, D). Thus, the combination of
chloroxine and carboplatin had an overall tumour-static
effect (average tumour radiance at endpoint 1.71 × 102
p/s/cm2/sr) compared to the carboplatin monotherapy
Dose (mg/Kg)
10 30 50 100A B















































































Fig. 2 In vivo activity for the combination of chloroxine (Chl. 10mg/kg) and carboplatin (50mg/kg) in intraperitoneal Ov4Carbo
xenografts. A Schematic of in vivo schedule, including treatment and bioluminescence imaging timeframe. B Representative images highlighting
maximum solubility of chloroxine (≤30 mg/kg) in intralipid 20%. C Representative bioluminescence images pre- and post treatment and light
emission over time. IP xenografts were created in female CD1nu/nu mice by injecting Ov4Carbo-Luc (5 × 106 cells per mouse). D Data depict different
treatment groups showing mean ± s.d., n= 4–14.
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group (average tumour radiance at endpoint 6.07 × 103p/
s/cm2/sr).
Chloroxine binds copper, but carboplatin synergy is
independent of its ionophore activity
8-hydroxyquinolines depict strong metal (Cu2+ and
Zn2+) binding activity17,20,21 that leads to proteasome
inhibition22, lysosome destabilisation23, ROS generation
and ultimately cell death. To investigate whether chlor-
oxine can also exhibit such activity, a chloroxine solution
was mixed in a 2:1 molar ratio with CuCl2. An intense
colour change was observed18, confirming the chemical
reaction typical for metal complex binding (Fig. 3A, inset).
We then sought to determine if this cupric-chloroxine
complex had relevant in vitro activity. When cells were
treated with the copper–chloroxine complex for 72 h,
potentiation of chloroxine cytotoxicity was observed (Fig.
3A), confirming that chloroxine can act as an ionophore.
However, when the copper–chloroxine complex was used
in combination with carboplatin, we observed a dramatic
reduction in cell viability. Raw luminescence units fol-
lowing treatment with the copper–chloroxine complex
were extremely low (<2000) preventing further inter-
pretation of any difference between the resulting
normalised values (Fig. 3B). These experiments demon-
strate that this complex behaves as a new cytotoxic metal
compound rather than mimicking chloroxine’s synergistic
interaction with carboplatin.
To further investigate whether this ionophore activity
could be responsible for the synergy we had observed, we
reproduced a more physiologically relevant copper envir-
onment in vitro by culturing cells in copper-enriched media
(10 μM) for 48 h prior to CellTiter-Glo assays. Although
the synergistic interaction of chloroxine and carboplatin
was once again verified, copper enrichment failed to alter
the activity of carboplatin alone and did not influence its
interaction with chloroxine in both OVCAR4 (Fig. 4A) and
Ov4Carbo cells (Fig. 4B). We also verified that CuCl2 alone
was non-toxic (Supplementary Fig. S3A) and contrary to
the complexation assays (Fig. 3A), copper-enriched media
did not alter the toxicity profile of chloroxine (Supple-
mentary Fig. S3B, C). Furthermore, enrichment assays
using higher copper concentrations (25 μM and 100 μM) in
short- (48 h) and long-term supplementation (7 days)
assays also failed to show any effect on drug synergy (data
not shown). These experiments imply that chloroxine-
mediated ionophore activity is unlikely to be responsible for
the synergy with carboplatin that we had observed.
Fig. 3 Role of copper (CuCl2) complexed with chloroxine in mediating carboplatin/chloroxine synergy in OVCAR4 (sensitive) and
OV4Carbo (resistant) HGSC cells. A IC50 plot for chloroxine (Chl) or chloroxine/CuCl2 complex (+CuCl2 10 μM). The inset shows representative
image of chloroxine mixed in a 2:1 molar ratio with CuCl2 in an ethanolic solution. The appearance of intensified yellow colour indicated formation of
a copper complex and B carboplatin+ chloroxine/CuCl2 complex (10 μM). Cell viability was determined using CellTiter-Glo
®. IC50 was calculated
using GraphPad Prism v.8.3.0. Mean ± s.d, n= 3, unpaired t test, **P < 0.01.
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Chloroxine does not alter platinum uptake or OPRK1
activity in vitro
Platinum uptake is mediated by both passive diffusion
and active transporters, and cells that fail to successfully
accumulate platinum, either by reduced import or
excessive export, have been shown to develop resistance8.
We measured whole-cell concentrations of platinum
using AAS (atomic absorption spectroscopy) after drug
treatment. Based on previous experimental procedures24,
we found that cell pellets treated with lysis buffer con-
taining 0.05% SDS, 1% triton and 0.5% HNO3 yielded
excellent recovery of platinum (Pt) signal (Supplementary
Fig. 5A). Standard curves confirmed the validity and lin-
earity of our assay (Y= 0.00187–0.054, R2= 0.9908) by
showing that carboplatin stock standards yielded equal Pt
signal to that of gold-standard Pt stocks. After carboplatin
treatment, platinum uptake was observed in both
OVCAR4 and Ov4Carbo cells, while vehicle- and
chloroxine-treated samples maintained baseline, back-
ground signal for the duration of the experiment (Sup-
plementary Fig. 5B, C). There was no significant
difference in platinum uptake between the two cell lines.
Further, the combination of chloroxine and carboplatin
did not influence Pt uptake, suggesting that synergy is not
dependant on intracellular Pt accumulation.
Two previous reports have described a possible function
of chloroxine as an inhibitor of the kappa opioid receptor,
OPRK125,26. To explore whether synergy between chlor-
oxine and carboplatin was mediated by OPRK1, we repe-
ated our established synergy assays with the addition of an
OPRK1 agonist (U50, 488) and antagonist (nor-BNI).
U50,488 (10 μM) did not alter carboplatin sensitivity
(Fig. 5D, dark-blue bar) and failed to reverse chloroxine’s
synergistic effect (Fig. 5D, light-grey bar). In addition, the
selective antagonist, nor-BNI27, also did not alter the dose
response to carboplatin (Fig. 5E, dark-blue bar), and had no
effect on chloroxine’s synergy with carboplatin (Fig. 5E,
light-grey bar). Taken together, these compounds did not
affect the cytotoxicity for carboplatin or the synergy we
observed between carboplatin + chloroxine (10 μM) (see
also Supplementary Fig. S4), implying that chloroxine was
not potentiating the effect of carboplatin through OPRK1-
mediated signalling pathways.
Chloroxine in combination with carboplatin regulates the
γ-H2AX–RAD51 axis and stabilises p53 in platinum-
resistant cells
We next evaluated the formation of DNA double-strand
breaks (DSB) and repair using the gold-standard markers,
γH2AX and RAD5128. Cells with >5 foci/nucleus were
Fig. 4 Role of copper (CuCl2)-enriched media in mediating carboplatin/chloroxine synergy in OVCAR4 (sensitive) and OV4Carbo (resistant)
HGSC cells. For enrichment assays, dose–response and IC50 plot for carboplatin+ chloroxine (10 μM) were determined in media enriched with CuCl2
(10 μM) for 48 h, in A OVCAR4 and B Ov4Carbo cells. Cell viability was determined using CellTiter-Glo®. IC50 was calculated using GraphPad Prism
v.8.3.0. Mean ± s.d, n= 3, group analysis was performed using one-way ANOVA with post hoc Kruskal–Wallis test, *P < 0.05, ns not significant.
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considered positive. Unsurprisingly, our IF data showed
that carboplatin induced high levels of γH2AX but very
infrequent RAD51 foci in OVCAR4 cells (Supplementary
Fig. S5A, B) consistent with their known platinum sensi-
tivity. Importantly, in this cell line, neither γH2AX nor
RAD51 foci were altered by chloroxine either alone or in
combination with carboplatin.
Single-agent chloroxine again did not alter γH2AX foci
in Ov4Carbo cells. However, all treatments, including
chloroxine alone, carboplatin alone and the combination,
induced RAD51 foci more effectively in Ov4Carbo than in
OVCAR4. This enhanced DNA repair capacity could
contribute to platinum resistance in these cells. In direct
contrast to OVCAR4 cells, by 4 h, combined chloroxine
and carboplatin treatment of Ov4Carbo cells had induced
more γH2AX foci than carboplatin alone, although this
was only observed with the lower dose of 50 μM carbo-
platin (P < 0.0001). This was followed by a significant
decline in RAD51 at 24 h (P= 0.0064) (Supplementary
Fig. 6A, B). These data were confirmed by co-localisation
analysis (Fig. 6C), which showed a significant reduction in
co-localised RAD51/γH2AX foci in Ov4Carbo, 24 h after
combined chloroxine and carboplatin treatment com-
pared to carboplatin alone.
These results were then corroborated by immunoblot-
ting, where OVCAR4 cells again expressed significantly
higher levels of γH2AX after treatment with carboplatin
(P < 0.01 compared to untreated cells) with no additional
Fig. 5 Analysis of platinum uptake and OPRK1-mediated synergy in OVCAR4 (sensitive) and Ov4Carbo (resistant) ovarian cancer cells.
A Standard curve generated from platinum gold standard (sigma) and carboplatin stock; comparison of platinum accumulation over time after
incubation with chloroxine (10 µM), carboplatin (100 µM) and combination of both drugs in (B) OVCAR4 and (C) Ov4Carbo. Pt quantity was
determined by AAS and normalised to total protein. IC50 plots for (D) OPRk1 agonist (U50-488, 10 µM) and (E) antagonist (nor-BNI, 10 µM), when used
in combination with carboplatin+ chloroxine. Cell viability was determined using CellTiter-Glo®. IC50 and linear regression (Y= 0.00187–0.054, R
2=
0.9908) was calculated using GraphPad Prism v.8.3.0. AAS assays: mean ± s.d., n= 3; agonist/antagonist assays: mean ± s.d., n= 8, unpaired t test, **P
< 0.01, *P < 0.05, ns not significant.
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Fig. 6 Subcellular analysis of γH2AX, RAD51 and p53 as markers of DNA damage/repair in Ov4Carbo (resistant) ovarian cancer cells. A
Representative immunofluorescent staining of γH2AX and RAD51, B foci quantification and C dot plot for Pearson’s correlation coefficients
representing co-localisation analysis after 4 and 24 h of treatment. (D) Representative immunoblots and densiometric analysis (normalised to tubulin
or GADPH), depicting γH2AX phosphorylation (Ser139), p53 and RAD51 expression. Cells were treated with chloroxine (10 μM), carboplatin I (50 μM),
combi. I (chloroxine 10 μM+ carboplatin 50 μM), carbo II (100 μM) or combi. II (chloroxine 10 μM+ carboplatin 100 μM). Untreated cells were used as
control. Quantification was expressed as percentage of cells that showed more than five γH2AX or RAD51 foci/nuclei at each time point. Data show
mean ± s.d., of individual ROI of duplicate coverslips. At least 100 cells were quantified for each independent experiment (IF and western blot: n ≥ 3
biological repeats). IF: two-way ANOVA with Tukey post hoc test; ****P < 0.0001, ***P < 0.001, **P < 0.01 and P > 0.05 (ns). WB: unpaired t test, ***P <
0.001 **P < 0.01, *P < 0.05 (compared to untreated) and ##P < 0.01, #P < 0.05 compared to carboplatin treated at each time point.
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change following combination treatment (ns) (Fig. 6D). In
contrast, Ov4Carbo cells depicted low levels of γH2AX
expression after exposure to carboplatin alone, but again
co-treatment with chloroxine significantly potentiated the
expression of γH2AX at both carboplatin doses (chlor-
oxine 10 μM+ carboplatin 50 μM: P= 0.0111 and chlor-
oxine 10 μM+ carboplatin 100 μM, P= 0.0012 compared
to carboplatin treatment alone). Despite the changes we
had observed in RAD51 localisation by IF, total expression
of RAD51 by western blot was stable over time and
comparable in the two cell lines (Fig. 6D). There was also
no significant difference in basal p53 expression between
the two cell lines (P= 0.08). We did, however, observe
increased p53 protein following combination treatment of
resistant Ov4Carbo cells (chloroxine 10 μM+ carboplatin
100 μM, P= 0.0318) but not sensitive OVCAR4 cells
(Fig. 6D). Together, our results show that chloroxine
co-treatment selectively facilitated carboplatin-induced
DNA damage in platinum-resistant cancer cells.
Chloroxine+ carboplatin abrogates G2/M cell cycle arrest
and triggers caspase 3/7-mediated cell death
To elucidate the downstream effects of DNA damage and
p53 stabilisation, we analysed cell cycle and cell death fol-
lowing carboplatin and chloroxine co-treatment. Carbopla-
tin treatment caused OVCAR4 cells to arrest in the S phase
at both 24 (Supplementary Fig. S6) and 48 h (Fig. 7A, B),
with concomitant accumulation of cells in subG1. In con-
trast, Ov4Carbo cells progressed through the cell cycle into
G2/M ( > 50% of the population at 48 h), despite platinum
treatment (Fig. 7A, B). Interestingly, in Ov4Carbo cells, this
carboplatin-induced G2/M arrest was abrogated after co-
treatment with chloroxine such that cell cycle profile mat-
ched that obtained when OVCAR4 cells were treated with
carboplatin alone. Together, this suggests that chloroxine
could restore the capacity of resistant cells to regulate cell
cycle and induce apoptosis following carboplatin treatment.
To further investigate this, we quantified caspase 3/7 activity.
When OVCAR4 cells were treated with either carboplatin or
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Fig. 7 Analysis of cell cycle profile and cell death in OVCAR4 (sensitive) and Ov4Carbo (resistant) ovarian cancer cells. A Representative
histograms 48 h post treatment; B cell cycle distribution (top) and percentage of sub/G1 apoptotic cells (bottom); C analysis of caspase 3/7 activity vs.
cell survival in OVCAR4 (left panel), Ov4Carbo (middle panel) and summary of assay (right panel). Cells were treated with chloroxine (10 μM), carbo II
(100 μM) or combi. II (chloroxine 10 μM+ carboplatin 100 μM). Untreated cells were used as control. Data show mean ± s.d., and percentage of G1
(2n), S and G2/M (4n) fraction population (FACs: n= 2; caspase 3/7: n= 3 biological repeats). Unpaired t test, ****P < 0.0001, *P < 0.05 (compared to
carboplatin treated).
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the combination of chloroxine and carboplatin, an increase
in caspase 3/7 activity was observed together with an
expected decrease in cell survival (Fig. 7C, left panel). There
was no difference in caspase 3/7 activity or cell survival in
this cell line when carboplatin and the chloroxine/carbo-
platin combination were compared. In contrast, when
Ov4Carbo cells were co-treated with carboplatin and
chloroxine, caspase 3/7 activity showed a striking twofold to
fivefold increase compared to carboplatin alone (Fig. 7C,
middle panel), correlating with the decrease in cell survival
and re-sensitisation to carboplatin that we had repeatedly
observed. Together, the addition of chloroxine allowed cell
cycle re-entry and potentiated carboplatin-induced cell
death in platinum-resistant HGSC cells.
Discussion
Despite HGSC’s initial high response rate to platinum
chemotherapy, patients eventually succumb to the disease
after developing gradual resistance to therapy. New drugs
that can circumvent resistance could have important
clinical implications. We show here for the first time that
the drug chloroxine has a strong synergistic effect with
both carboplatin and cisplatin in a range of HGSC cell
lines and in vivo models.
Chloroxine is a 8-HQ derivative. This family of drugs
have the potential to form metal complexes via copper
and zinc binding18,20,21, acting as proteasome inhibitors22
or triggering apoptosis23,29. Although we confirmed the
ionophore activity of chloroxine, neither copper com-
plexation nor intracellular uptake of either copper or
platinum appeared to mediate the re-sensitisation to
platinum that we observed. Equally, we were unable to
demonstrate that a predicted pharmacological function
for chloroxine as an inhibitor of kappa opioid receptors
accounted for drug synergy.
HGSC is characterised by genomic instability with
pervasive TP53 mutation30–32. Homologous recombina-
tion and repair dysfunction is also critical in the patho-
genesis of this disease33, and cellular responses to
carboplatin-induced damage are highly dependent on the
proficiency of cell cycle and DDR pathways5,7. The status
of TP53 has generated controversy around drug response
in vitro34; thus, it is imperative to use clinically relevant
HGSC models such as OVCAR435, in order to understand
the relationship of TP53 to mechanisms, including the
DDR. Over 60% of TP53-associated mutations are mis-
sense mutations36,37, which have been described for
OVCAR4 cells37,38 and are commonly associated with
gain-of-function properties. We show here that chlorox-
ine may well interfere with the DDR, and that stabilisation
of p53 in otherwise mutant cells is linked to cell death.
Our data are comparable to other reports7,39–41, show-
ing that sensitive OVCAR4 cells can stall DNA replication
in G1/S phase in response to single-agent platinum
treatment. In addition, OVCAR4 cells exhibited minimal
RAD51 focus formation, which could potentially indicate
a reduced DNA repair capacity and thus higher sensitivity
of OVCAR4 cells to platinum drugs. Although there was
no difference in total RAD51 protein expression between
the two cell lines, Ov4Carbo cells were able to induce
RAD51 foci in response to platinum treatment. These
enhanced DNA repair dynamics may explain the relative
platinum resistance of Ov4Carbo cells and matches with
our previous RNASeq analysis that revealed an increase in
the DNA recombination pathway in Ov4Carbo compared
to OVCAR4 cells13.
Chloroxine treatment alone had minimal impact on
γH2AX and RAD51 foci in either cell line. Platinum-
sensitive OVCAR4 cells were able to efficiently respond to
single-agent carboplatin treatment by increasing γH2AX
foci formation at all carboplatin doses and time points
tested. In these platinum-sensitive cells, the addition of
chloroxine did not increase γH2AX above the high
γH2AX activation that had already been achieved with
carboplatin alone. In contrast, platinum-resistant
Ov4Carbo cells did not induce γH2AX foci in response
to the lower dose of 50 µM carboplatin, but the addition
of chloroxine was able to override this apparent resistance
to carboplatin-induced DNA damage and significantly
enhance γH2AX accumulation compared to single-agent
carboplatin treatment. Importantly, the very high carbo-
platin dose of 100 µM was able to induce γH2AX foci
even in resistant Ov4Carbo cells and once this had been
achieved, chloroxine again did not augment γH2AX any
further. It is interesting to note that by western blot, we
did detect significantly elevated γH2AX protein in
Ov4Carbo cells following co-treatment with chloroxine at
both carboplatin doses, perhaps reflecting different sen-
sitivity of these two assays. Induction of γH2AX foci by
combination treatment of Ov4Carbo cells was followed by
a decrease in RAD51 recruitment. This accumulation of
DNA damage would be expected to result in the
p53 stabilisation, cell cycle stalling in G1/S and apoptotic
cell death that we observed42,43. Treatments that can
reactivate mutant p53 protein have been shown to
potentiate chemotherapy and induce apoptosis44, sug-
gesting that chloroxine may exhibit a similar activity45.
In conclusion, we have demonstrated that the non-
oncological drug chloroxine potentiates the cytotoxicity
of carboplatin in resistant subtypes of HGSC. Chloroxine
synergy was extended to different platinum agents and a
range of cell lines and showed a strong tumour-static
effect in vivo. Our data suggest that this synergy is
mediated via the persistence and dysfunctional repair of
platinum-induced damage, along with p53 stabilisation.
We, therefore, propose that chloroxine warrants further
investigation as an exciting new combination therapy to
target resistant subtypes of HGSC.
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